Search Results for "Saxenda"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Saxenda. Results 11 to 15 of 15 total matches.
Tirzepatide (Zepbound) for Obstructive Sleep Apnea
The Medical Letter on Drugs and Therapeutics • Feb 17, 2025 (Issue 1722)
in treating OSA.
Other GLP-1 Receptor Agonists – Liraglutide (Saxenda)
has also been shown to reduce AHI ...
The injectable glucose-dependent insulinotropic
polypeptide (GIP)/glucagon-like peptide-1 (GLP-1)
receptor agonist tirzepatide (Zepbound) has been
approved by the FDA for treatment of moderate to
severe obstructive sleep apnea (OSA) in adults with
obesity. It is the first drug to be approved in the US for
this indication. Zepbound is also approved for chronic
weight management in adults with obesity and in those
who are overweight and have at least one weightrelated
comorbidity. Tirzepatide is also available as
Mounjaro for treatment of type 2 diabetes.
Med Lett Drugs Ther. 2025 Feb 17;67(1722):29-31 doi:10.58347/tml.2025.1722c | Show Introduction Hide Introduction
Comparison Table: Some FDA-Approved Drugs for Weight Management (online only)
The Medical Letter on Drugs and Therapeutics • May 30, 2022 (Issue 1651)
– generic
Saxenda (Novo Nordisk)
18 mg/3 mL pens 3 mg SC once/day
Titration: 0.6 mg once/day x 7 days ...
View the Comparison Table: Some FDA-Approved Drugs for Weight Management
Contrave - A Combination of Bupropion and Naltrexone for Weight Loss
The Medical Letter on Drugs and Therapeutics • Nov 10, 2014 (Issue 1455)
under review by the FDA (as Saxenda) for
treatment of obesity.
MECHANISM OF ACTION — Bupropion ...
The FDA has approved a fixed-dose combination of
the opioid receptor antagonist naltrexone (ReVia, and
others) and the antidepressant and smoking cessation
agent bupropion (Wellbutrin SR, Zyban, and others),
as Contrave (Orexigen/Takeda) for weight loss. The
combination was approved for use as an adjunct to
diet and increased physical activity in patients with a
body mass index (BMI) ≥30 kg/m2 or a BMI ≥27 kg/m2
and one or more weight-related comorbidities such as
hypertension, diabetes, or dyslipidemia. Naltrexone/bupropion is not a controlled...
Drugs and Devices for Weight Management
The Medical Letter on Drugs and Therapeutics • May 30, 2022 (Issue 1651)
– Saxenda (Novo Nordisk) 18 mg/3 mL prefilled pen13 3 mg SC once/day14 5.6-8.4 kg/51-63%15,16 1349.00 ...
Adults with a body mass index (BMI) between 25
and 29.9 kg/m2 are considered overweight. Those
with a BMI ≥30 are considered obese. The initial
recommendation for any weight loss effort is to
achieve a 5-10% reduction in weight, which has been
associated with a reduction in the risk of developing
type 2 diabetes, hypertension, and dyslipidemia. Diet,
exercise, and behavior modification are the preferred
methods for losing weight, but long-term weight
maintenance can be difficult. Several drugs and
devices are FDA-approved for weight reduction and
maintenance of weight...
Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
.30
Subcutaneous semaglutide (Wegovy) and liraglutide
(Saxenda) are FDA-approved for chronic weight ...
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
require antihyperglycemic drug therapy. Treating to
a target A1C of <7% while minimizing hypoglycemia
is recommended to prevent microvascular complications
of diabetes (retinopathy, nephropathy, and
neuropathy). An A1C target of <8% may be appropriate
for some older patients.